Clinical Trials | May 14, 2026
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Subscribe To Our Newsletter & Stay Updated
